4D Molecular Therapeutics Inc Cash Flow Conversion Efficiency
4D Molecular Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, 4D Molecular Therapeutics Inc (FDMT) has a cash flow conversion efficiency ratio of 0.056x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($28.55 Million) by net assets ($505.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of 4D Molecular Therapeutics Inc (2017–2025)
Cash flow conversion efficiency of 4D Molecular Therapeutics Inc from 2017 to 2025. This chart illustrates how 4D Molecular Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for 4D Molecular Therapeutics Inc for real-time trading data and today's change.
4D Molecular Therapeutics Inc Cash Flow Conversion Ratio Explained
4D Molecular Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
4D Molecular Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 4D Molecular Therapeutics Inc ranked by their cash flow conversion efficiency. Also see how much is 4D Molecular Therapeutics Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Puyang Refractories Group Co Ltd
SHE:002225
|
0.011x |
|
Veradigm Inc.
NASDAQ:MDRX
|
0.024x |
|
Zevra Therapeutics Inc.
NASDAQ:ZVRA
|
0.035x |
|
Zhejiang Zoenn Design Co Ltd
SHE:300901
|
0.050x |
|
Marssenger Kitchenware Co. Ltd.
SHE:300894
|
-0.054x |
|
Hainan Pearl River Holdings Co Ltd
SHE:000505
|
-0.023x |
|
Grand Industrial Holding Co Ltd
SHE:000626
|
0.146x |
|
Shanghai Golden Union Commercial Management Co Ltd
SHG:603682
|
0.144x |
Annual Cash Flow Conversion Efficiency for 4D Molecular Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of 4D Molecular Therapeutics Inc from 2017 to 2025. Review how much free cash does 4D Molecular Therapeutics Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $505.66 Million | $-109.08 Million | -0.216x | +18.16% |
| 2024-12-31 | $510.61 Million | $-134.59 Million | -0.264x | -7.05% |
| 2023-12-31 | $307.83 Million | $-75.79 Million | -0.246x | +34.29% |
| 2022-12-31 | $231.34 Million | $-86.69 Million | -0.375x | -72.96% |
| 2021-12-31 | $319.11 Million | $-69.13 Million | -0.217x | -9.11% |
| 2020-12-31 | $256.39 Million | $-50.91 Million | -0.199x | -139.47% |
| 2019-12-31 | $-72.97 Million | $-36.71 Million | 0.503x | -14.60% |
| 2018-12-31 | $-27.59 Million | $-16.25 Million | 0.589x | +240.11% |
| 2017-12-31 | $-19.59 Million | $8.24 Million | -0.420x | -- |
About 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production o… Read more